Heart Transplant Rejection
📧 Sign up to get email alerts when something new happens for Heart Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-11-16FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited.
-
FDA approval · 2022-08-10FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil) filed by Genentech, updating the labeling to reflect the approv…
-
FDA approval · 2022-08-10FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil hydrochloride) submitted by Genentech, Inc.
-
FDA approval · 2022-03-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for mycophenolate mofetil (generic) submitted by Mylan Pharmaceuticals, granting approval under an A…
-
FDA approval · 2021-11-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Biocon Pharma Inc.)
FDA approved an original application for mycophenolic acid (Biocon Pharma Inc.), establishing a generic version of the immunosuppressant.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved Genentech's supplemental application for CELLCEPT (mycophenolate mofetil).
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCEPT (mycophenolate mofetil) submitted by Genentech, updating regulatory status for addition…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for mycophenolate mofetil submitted by Hikma Pharmaceuticals USA Inc., updating the product info…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for mycophenolate mofetil submitted by Sandoz Inc.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Accord Healthcare, resulting in updated product labeling.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for mycophenolic acid submitted by Apotex Corp.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Hikma Pharmaceuticals USA Inc., indicating an approved change to the …
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for Mycophenolate mofetil (ANDA 065416) from Accord Healthcare Inc., updating the status of this…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Mycophenolate mofetil from Mylan Pharmaceuticals Inc., updating the regulatory status for th…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Mycophenolate mofetil, submitted by Mylan Institutional LLC, potentially expanding labeling or i…
-
FDA approval · 2021-07-16FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) from Astellas Pharma US, expanding or updating its labeling and indications…
-
FDA approval · 2021-05-17FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Hikma's generic mycophenolate mofetil, authorizing its marketing for organ transplant rejection …
-
FDA approval · 2021-05-17FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for mycophenolate mofetil from Hikma Pharmaceuticals USA Inc., approving changes to the product'…
-
FDA approval · 2021-05-17FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for mycophenolate mofetil from Sandoz Inc.
-
FDA approval · 2021-05-17FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare's supplemental application for mycophenolate mofetil. The generic product is approved for use in preventing o…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation [Phase 3]
Phase 3 trial evaluating de-novo use of eculizumab in presensitized cardiac transplant patients completed; results posted in 2021.
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for mycophenolate mofetil from Mylan Pharmaceuticals, indicating an approved change to the exist…
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for mycophenolate mofetil from Ascend Laboratories, LLC.
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil by Concord Biotech Limited, enabling continued marketing of the immunosupp…